ALX Oncology Holdings Reports Shareholder Vote Matters
Ticker: ALXO · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1810182
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ALXO
TL;DR
ALXO filed an 8-K about a shareholder vote - watch for updates on corporate decisions.
AI Summary
ALX Oncology Holdings Inc. filed an 8-K on June 17, 2024, reporting an event that occurred on June 12, 2024. This filing pertains to the submission of matters to a vote of security holders, indicating a shareholder meeting or vote is scheduled or has taken place. The company is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This filing signals important corporate actions requiring shareholder approval, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: medium — Filings related to shareholder votes can introduce uncertainty regarding corporate governance and strategic decisions.
Key Players & Entities
- ALX ONCOLOGY HOLDINGS INC (company) — Registrant
- June 12, 2024 (date) — Earliest event reported
- June 17, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
- 001-39386 (commission_file_number) — SEC File Number
FAQ
What specific matters were submitted for a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 12, 2024.
What is the principal executive office address for ALX Oncology Holdings Inc.?
The principal executive office address is 323 Allerton Avenue, South San Francisco, California 94080.
What is the SEC file number for ALX Oncology Holdings Inc.?
The SEC file number for ALX Oncology Holdings Inc. is 001-39386.
What is the standard industrial classification for ALX Oncology Holdings Inc.?
The standard industrial classification for ALX Oncology Holdings Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-06-17 16:21:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
Filing Documents
- alxo-20240612.htm (8-K) — 57KB
- 0000950170-24-074258.txt ( ) — 168KB
- alxo-20240612.xsd (EX-101.SCH) — 25KB
- alxo-20240612_htm.xml (XML) — 4KB
07 Submission of matters to a vote of security holders
Item 5.07 Submission of matters to a vote of security holders. ALX Oncology Holdings Inc. (the "Company") held its Annual Meeting of stockholders (the "Annual Meeting") on June 12, 2024. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. Proposal 1: Election of Three Class I Directors Name of Director For Withheld Broker Non-Votes Corey Goodman, Ph.D. 35,775,363 6,616,621 5,320,757 Jason Lettmann 33,828,276 8,563,708 5,320,757 Sophia Randolph, Ph.D. 28,671,086 13,720,898 5,320,757 Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal. Proposal 2: Advisory Vote on the Compensation of the Company's Named Executive Officers For Against Abstain Broker Non-Votes 40,935,354 1,422,239 34,391 5,320,757 The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting. Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 47,698,670 11,338 2,733 The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALX ONCOLOGY HOLDINGS INC. Date: June 17, 2024 By: /s/ Peter Garcia Peter Garcia Chief Financial Officer 2